temozolomide,Ibrutinib,Rituximab,Doxorubicin,Dexamethasone
abbvie,janssen
['ibru']
patients who respond to ibrutinib lead-in more likely to do well to tedd(i)-r for secondary cnsl. cd10 negativity may be a marker for ibrutinib sensitivity. #17icml 
#Lymphoma Doc. Faculty at @UCIrvineHealth. Buffalo born, @HarvardMed trained. Tweets are mine & not medical advice.